

CUPID LIMITED

Manufacturers and Suppliers of Male & Female Condoms

Date: - 30/01/2023

To,

Department of Corporate Services,

BSE LIMITED,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

SCRIP CODE: 530843

The National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Bandra-Kurla

Complex, Bandra (East),

Mumbai - 400051

Fax No. - 6641 8125 / 26

SCRIP CODE: CUPID

Subject: - Outcome of Board Meeting and Financial Results for Quarter ended 31st December, 2022

Dear Sir / Madam,

With reference to captioned subject, we attached herewith the detail statement of outcome of Board Meeting and Financial Results for quarter and nine months ended 31st December, 2022 pursuant to regulation 30 and regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 respectively.

Kindly take the same on your records and acknowledge the receipt.

By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer

ECSIN: EA041701A000083921

CIN No.: L25193MH1993PLC070846



CUPID LIMITED

Manufacturers and Suppliers of Male & Female Condoms

OUTCOME OF BOARD MEETING

January 30th, 2023:

The Board of Directors of the Cupid Limited at its meeting held on January 30th, 2023, inter alia, had considered and approved the following matters:-

Commencement time of Board Meeting: - 05.00 P.M.

Conclusion time of Board Meeting: - 05.35 P.M.

- Quarterly reports submitted to BSE Limited and National Stock Exchange of India Limited for quarter ended 31st December, 2022 were considered and reviewed by the Board.
- Unaudited Financial Results for quarter and nine months ended 31st December, 2022 were considered and adopted by the Board. (Financial Results as attached)

Place: - Mumbai

Date: - 30/01/2023

By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer

ECSIN: EA041701A000083921

CIN No.: L25193MH1993PLC070846

Partners:
Sohan Chaturvedi FCA
Chaturvedi V N FCA
Noshir B Captain
Rajiv Chauhan ACA
Neha Chauhan ACA
Shristi Chaturvedi ACA
Prakash Mistry FCA



Chaturvedi Sohan & Co.

Chartered Accountants

FRN - 118424W

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Limited Review Report to The Board of Directors CUPID LIMIED

- 1. We have reviewed the accompanying statement of unaudited financial results of Cupid Ltd (the "Company") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with standards on Auditing specifies under section 143(10) of the Act. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid' Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of

the SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi Sohan & co. **Chartered Accountants**

FRN: 118424W

Vivekanand Chaturvedi

Partner

Membership No. 106403 UDIN: 23106403 B4P0QV8720

Place: Mumbai

Date: 30.01.2023

Cupid Limited

CIN No : L25193MH1993PLC070846

Regd. Office: - A-68, M.I.D.C. (Malegaon), Sinnar, Nashik – 422113, Maharashtra, India. Ph:- 02551-230280, Fax:- 02551-230279, Website: www.cupidlimited.com, Email- info@cupidlimited.com

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended 31st December, 2022

_	P. Comments of the comments of			(₹ in	Lacs except EP	S data, unless o	
	Name and the contract of the c		Quarter Ended	On	Nine Mont	hs Ended on	Year Ended on
S.No.	Particulars	31-Dec-2022	30-Sep-2022	31-Dec-2021	31-Dec-2022	31-Dec-2021	31-Mar-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operation	4,176.35	4,524.94	3,622.32	11,782.91	10,137.04	13,273.46
2	Other Non - operation Incomes	115.19	95.57	75.82	278.01	325.07	431.27
	Total Income	4,291.54	4,620.51	3,698.14	12,060.92	10,462.11	13,704.73
3	Expenses						
a)	Cost of Material Consumed	1,349.58	2,017.20	1,488.58	4,985.84	4,424.37	6,307.18
b)	Change in Inventories	106.93	(272.81)	459.80	(311.17)	231.74	(108.29
c)	Employee benefit expenses	306.18	295.98	262.61	887.84	843.71	1,091.23
d)	Finance costs	7.61	6.47	3.59	21.88	9.66	13.45
e)	Depreciation	77.88	70.90	62.21	213.99	184.06	264.61
f)	Other Expenses	1,121.43	1,284.55	1,051.76	3,149.65	2,993.09	3,684.45
	Total Expenses	2,969.61	3,402.29	3,328.55	8,948.03	8,686.63	11,252.63
4	Profit from Continuing Operation Before Exceptional items and Taxes	1,321.93	1,218.22	369.59	3,112.89	1,775.48	2,452.10
5	Profit From Ordinary Activities Before Tax	1,321.93	1,218.22	369.59	3,112.89	1,775.48	2,452.10
6 a) b) c)	Less: Tax Expenses Income tax for current quarter/ year Short / (Excess) provision of earlier years Deferred Tax Expenses / (Credit)	331.14	325.71 - 34.55	101.92 - 18.28	827.81	432.13	660.81 48.27 15.08
7	Net Profit / (Loss) From Ordinary Activities after tax for the period	1,003.33	857.96	249.39	2,324.73	1,309.09	1,727.94
8	Other Comprehensive Income / (Loss) (Net of Tax)					SECURITY SHOWS FOR	
a)	Item that will not be reclassified to profit and loss account						
	Remeasurement of en-ployee defined benefit obligation	(8.93)		-	(8.93)	(8.16)	7.84
	Income Tax relating to items that will not be reclassified to profit or loss	2.25			2.25	2.05	(1.97)
9	Total Comprehensive Income (after tax) for the period	996.65	857.96	249.39	2,318.05	1,302.98	1,733.80
10	Paid up Equity Share Capital (Face value Rs.10/-)	1,333.80	1,333.80	1,333.80	1,333.80	1,333.80	1,333.80
11	Earning Per Share (EPS) (* Not Annualised)	W. 777	4.75				
a)	Basic EPS (Amount is ₹)	7.52*	6.43*	1.87*	17.43*	9.81*	12.95
b)	Diluted EPS (Amount is ₹)	7.52*	6.43*	1.87*	17.43*	9.81*	12.95



Segment Revenue a) Male and Female Contraceptives & Jelly b) In Vitro Devices (IVD) c) Others / Unallocated	21 Dec 2022	Onarter Fuded on				(< in Lacs)
Segment Revenue a) Male and Female Contraceptives & Jelly b) In Vitro Devices (IVD) c) Others / Unallocated	/ - John -	30 Con 2022	21.00	Nine Month	Nine Months Ended on	Year Ended on
Segment Revenue a) Male and Female Contraceptives & Jelly b) In Vitro Devices (IVD) c) Others / Unallocated	(Hanneltod)	7707-dac-oc	31-Dec-2021	31-Dec-2022	31-Dec-2021	31-Mar-2022
a) Male and Female Contraceptives & Jelly b) In Vitro Devices (IVD) c) Others / Unallocated	(Ouzudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
b) In Vitro Devices (IVD) c) Others / Unallocated	4 169 30	4 501 40		2000 MINOR MANAGEMENT (2000)		7
c) Others / Unallocated	6 06	4,321.42	3,622.32	11,772.29	9,764.88	12,901.30
	0.30	3.52		10.62	372.16	372.16
	61.611	95.57	75.82	278.01	325.07	431.27
Total	4 291 54	12 000 4	3,000 41	-		
Less: Inter Segment Revenue		10.040,7	3,098.14	12,060.92	10,462.11	13,704.73
Gross Revenue from sale of product & Service	1,301,51		-			
	4,271.34	4,620.51	3,698.14	12,060.92	10,462.11	13,704.73
2 Segment Results Profit/(Loss) Before Tax						
a) Male and Female Contraceptives & Jelly	1.253.38	1 140 20	00 100			
b) In Vitro Devices (IVD)	(46.64)	07.01.1	294.98	2,954.19	1,360.66	1,991.67
c) Others / Unallocated	(40.04)	((32./1)	(1.21)	(119.31)	89.75	29.16
	91.611	95.57	75.82	278.01	325.07	431.27
Total Profit Before Tax	1,321.93	1 216 33	02.076			
	200	77.017.1	96,295	3,112.89	1,775.48	2,452.10
3 Segment Assets						
a) Male and Female Contraceptives & Jelly	7.533.28	7 066 71				
b) In Vitro Devices (IVD)	788.13	730 04	7,700.44	7,533.28	7,766.44	8,080.85
c) Others / Unallocated	10 822 34	10.764.01	2000.32	/88.13	560.52	812.47
	10,042.34	10,304.93	7,489.93	10,822.34	7,489.93	7,975.38
Total Assets	19,143.75	19,062.58	15,816.89	19,143.75	15.816.80	02 070 71
1 (1 1) 1 (1) 1 (1)						0/2000401
a) Male and Female Contraceptives & Jelly	2,122.87	2,668.88	1,510.01	2 122 87	1 510 01	200
b) vitro Diagnostic Device (IVD)	59.90	672.07	38 79	20.00	10.010.1	7,730.02
c) Others / Unallocated	1,151.33	672.07	539.19	1,151.33	539.19	347.47
Total Liabilities	3.334.10	4 013 02	00 200 0			



NOTES TO THE QUARTERLY RESULT: -

 The above unaudited standalone financial results were reviewed by the Audit Committee and have been approved by the Board of Director at its meeting held on 30th January, 2023.

 Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principle of Ind AS notified under the Companies (Indian Accounting Standard) Rules, 2015 as amended from time to time.

3. The company's business operation comprises of operating segments viz., Male and Female contraceptives, other relevant products and In Vitro Devices (IVD).

 The Board of Directors authorised Mr. Omprakash Garg, Managing director to sign the standalone financial results of the company for quarter & nine months ended on 31st December, 2022.

5. The previous period / year financial figures have been regrouped / rearranged wherever necessary to make them comparable.

6. During this quarter, company has transferred unclaimed and unpaid dividend of ₹7,64,902 and 2,655 unclaimed shares to Investor Education and Protection Fund (IEPF).

7. The results of the Company are available for investors at https://www.cupidlimited.com/, https://www.nseindia.com/ and https://www.bseindia.com/

Place: Mumbai

Date: 30th January, 2023

For and on behalf of Cupid Limited

Omprakash Garg Managing Director